Claritev Corporation (NYSE: CTEV) is a Healthcare company (Medical - Healthcare Information Services) with a market capitalization of $392M. The Maz Rating grades it against the other companies in its sector.
Claritev Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $22.95, Claritev Corporation trades at 0.4x sales, with an EV/EBITDA of 10.3. Over the last twelve months it generated about $1.0B of revenue and a net loss of $280M. It runs a gross margin of 33.8%, an operating margin of 5.8% and a net margin of -27.1%. It shows return on equity of 104.2%, return on invested capital of 1.0% and a free cash flow yield of -7.2%. On the balance sheet: a debt-to-equity ratio of -13.37 and a current ratio of 1.15. Over the past 52 weeks the share price ranged from $11.50 to $55.50, with a beta of 0.79.
Claritev Corporation does not currently pay a dividend.
6 Wall Street analyst ratings cover the stock: 5 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Claritev Corporation, together with its affiliated companies, provides advanced data analytics and technology-enabled services focused on cost management, payment optimization, and revenue assurance for the healthcare sector across the United States. The company offers a suite of services designed to reduce medical expenses. This includes analytics-driven solutions that utilize sophisticated algorithms and data insights to pinpoint billing overcharges, subsequently assisting with or recommending appropriate reimbursement negotiations. Additionally, their network-focused services secure discounted rates through contracts with healthcare providers and provide outsourced administration for these provider networks. Claritev also specializes in payment and revenue integrity, identifying and removing erroneous or unwarranted charges processed during claims, while simultaneously working to identify, recover, and safeguard underpaid premium amounts. Furthermore, their data and decision science offerings encompass a range of solutions that apply modern data science methodologies—including descriptive, predictive, and prescriptive analytics—to refine benefit plan structures, aid strategic decision-making, enhance patient clinical results, and ultimately lower overall healthcare costs. The company also handles business-to-business healthcare payment processing and other related services. Their diverse clientele includes major national and regional insurance carriers, Blue Cross and Blue Shield organizations, various provider-sponsored and independent health plans, third-party administrators (TPAs), self-insured health plans, property and casualty insurers, bill review firms, and other entities involved in the claims settlement process. Established in 1980 and headquartered in New York, New York, Claritev Corporation was previously known as MultiPlan Corporation before officially adopting its current name in February 2025.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Claritev Corporation (CTEV) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 957.1% / 30% · (Cash+Inv) / Mkt Cap (36m) 2.09% / 30% · Interest income / Revenue -0.09% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 957.1% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 2.09% / 33% · Receivables / Mkt Cap (36m) 31.9% / 49% · Interest income / Revenue -0.09% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 957.1% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 2.09% / 33.33% · Receivables / Mkt Cap (24m) 31.9% / 33.33% · Interest income / Revenue -0.09% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 96.4% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 0.33% / 33.33% · Receivables / Avg Assets (4Q) 3.11% / 33.33% · Interest income / Revenue -0.09% / 5% | Fail |
| FTSE | Debt / Total Assets 99.1% / 33.33% · (Cash+ST Inv) / Total Assets 0.22% / 33.33% · (Cash+Recv) / Total Assets 3.52% / 33.33% · Interest income / Revenue -0.09% / 5% | Fail |
No. As of September 2026, Claritev Corporation (CTEV) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Claritev Corporation is over the AAOIFI limit on Debt / Mkt Cap (36m).
Claritev Corporation reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.